NKA Bio
Techstars '24Baltimore, US · 2 known investors
NKA Bio develops antibody-based medicines for critically ill and trauma patients to extend survival time during medical emergencies. The company's lead candidate, NKA01, is an anti-shock toxin antibody administered by emergency medical services to stabilize trauma patients and buy time for transport and surgical intervention.
Founders & leadership
Do
Director of Emergency Medicine at Johns Hopkins